tell me about liver cirrhosis in brief

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive content from Robbins Pathology, Goldman-Cecil Medicine, and Guyton & Hall. I have enough to provide a thorough, well-cited answer.

Liver Cirrhosis

Cirrhotic liver showing broad scars and regenerative nodules on its surface

Gross specimen of a cirrhotic liver — broad fibrous scars separating bulging regenerative nodules (Robbins & Kumar Basic Pathology)

Definition

Cirrhosis is the diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands. It represents the end stage of any chronic liver disease and is not a single specific entity — its morphology, pathophysiology, and prognosis vary by underlying cause.

— Robbins & Kumar Basic Pathology, p. 598

Causes

Most common worldwide:

Chronic Hepatitis B
Chronic Hepatitis C
Non-alcoholic fatty liver disease (NAFLD/NASH)
Alcohol-related liver disease

Less common (<2% of cases):

Primary biliary cirrhosis / Primary sclerosing cholangitis
Autoimmune hepatitis
Metabolic disorders: Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, glycogen storage diseases
Biliary obstruction / biliary atresia / cystic fibrosis
Hepatic venous outflow obstruction (Budd-Chiari)
Cryptogenic cirrhosis — when no cause is identified

— Goldman-Cecil Medicine, p. 1614–1615

Pathogenesis

The central cellular event is activation of hepatic stellate cells (Ito cells / perisinusoidal cells):

Normally quiescent, they reside in the Space of Disse and store retinoids (vitamin A)
On injury, they lose vitamin A, proliferate, develop rough endoplasmic reticulum, and secrete extracellular matrix (collagen types I and III, sulfated proteoglycans, glycoproteins)
They transform into contractile myofibroblasts, driving fibrosis
Fibrous septa link portal tracts to each other and to central veins, distorting hepatic architecture
Surviving hepatocytes undergo regeneration, forming nodules, but these lack normal vascular organization

Importantly, fibrosis can regress if the underlying injury is removed (e.g., cured hepatitis C, treated autoimmune hepatitis) — scars compact, thin, and fragment, allowing nodule coalescence.

— Goldman-Cecil Medicine, p. 1614; Robbins & Kumar, p. 598

Morphology

Gross: Nodular surface, orange-tawny color, irregular texture (vs. smooth normal liver)
Microscopic: Disorganized architecture with regenerative nodules surrounded by fibrous tissue; prominent ductular reactions (stem cell-derived duct-like structures increase with disease progression)
Nodule size and scar pattern vary by etiology

Staging: Compensated vs. Decompensated

Stage	Definition
Compensated	Cirrhosis present but no major complications; may be asymptomatic (~40% of patients)
Decompensated	Development of ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice

Decompensation is driven by portal hypertension (and the hyperdynamic circulatory state) and/or liver insufficiency. Each stage has different predominant pathophysiologic mechanisms and management strategies.

— Goldman-Cecil Medicine, p. 1614

Clinical Features

Asymptomatic / nonspecific early:

Anorexia, weight loss, weakness, fatigue

Manifestations of liver failure:

Jaundice — chronic severe jaundice causes pruritus (from bile salt accumulation), which can be debilitating
Coagulopathy — decreased synthesis of clotting factors
Hepatic encephalopathy — altered mentation from nitrogenous waste accumulation

Portal hypertension complications:

Ascites — raised portal pressure + reduced plasma oncotic pressure (from low albumin synthesis) causes fluid leakage into the peritoneal cavity; kidneys compensate by retaining salt and water
Esophageal/gastric varices — portosystemic collaterals; rupture causes life-threatening hemorrhage
Splenomegaly — splenic congestion → hypersplenism (thrombocytopenia, leukopenia)
Caput medusae — dilated periumbilical veins

Other systemic effects:

Spider angiomata, palmar erythema, gynecomastia (altered hormone metabolism)
Hepatorenal syndrome — functional renal failure
Hepatopulmonary syndrome / portopulmonary hypertension
Increased risk of hepatocellular carcinoma (HCC)

Fluid/electrolyte physiology: Reduced plasma proteins → reduced oncotic pressure; portal obstruction → raised capillary pressure → ascites. The kidneys retain Na⁺ and water to restore volume; vascular capacity may actually increase due to portal vein distension, perpetuating fluid retention.

— Guyton and Hall Textbook of Medical Physiology; Robbins & Kumar, p. 598–599

Diagnosis

LFTs: Elevated bilirubin, AST/ALT (may be normal in end-stage), low albumin, prolonged PT/INR
CBC: Thrombocytopenia (hypersplenism), anemia
Imaging (US/CT/MRI): Nodular liver surface, splenomegaly, ascites, collateral vessels
Elastography (FibroScan): Non-invasive fibrosis assessment
Liver biopsy: Gold standard for confirming cirrhosis and identifying etiology
MELD score (Model for End-stage Liver Disease): Predicts 90-day mortality using bilirubin, INR, creatinine

Management Principles

Treat the underlying cause — antiviral therapy for hepatitis B/C, alcohol abstinence, weight loss for NAFLD
Prevent and manage complications:
- Ascites: Sodium restriction, diuretics (spironolactone ± furosemide), paracentesis for refractory cases
- Varices: Non-selective beta-blockers (propranolol/nadolol) for primary prophylaxis; endoscopic band ligation; TIPS (transjugular intrahepatic portosystemic shunt) for refractory bleeding
- Encephalopathy: Lactulose, rifaximin, dietary protein adjustment
- Spontaneous bacterial peritonitis (SBP): IV antibiotics (cefotaxime), long-term norfloxacin prophylaxis
Liver transplantation — definitive treatment for decompensated cirrhosis; selection based on MELD score

Key Points Summary

Feature	Detail
Core pathology	Nodules + fibrous bands throughout liver
Key cellular event	Hepatic stellate cell activation
Main causes	Alcohol, NAFLD, Hep B, Hep C
Decompensation triggers	Ascites, varices, encephalopathy, jaundice
Reversibility	Possible in early stages if cause removed
Complication to screen	HCC (6-monthly USS + AFP)

This is a shared conversation. Sign in to Orris to start your own chat.